Logo image of GRX

GABELLI HEALTHCARE & WELL (GRX) Stock Overview

USA - NYSE:GRX - US36246K1034

9.27 USD
+0.04 (+0.43%)
Last: 10/8/2025, 8:04:00 PM
Fundamental Rating

2

GRX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 0 industry peers in the Unkown industry. While GRX seems to be doing ok healthwise, there are quite some concerns on its profitability. GRX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year GRX has reported negative net income.
GRX had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: GRX reported negative net income in multiple years.
GRX had a positive operating cash flow in 4 of the past 5 years.
GRX Yearly Net Income VS EBIT VS OCF VS FCFGRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

1.2 Ratios

Industry RankSector Rank
ROA -0.36%
ROE -0.43%
ROIC N/A
ROA(3y)-6.34%
ROA(5y)0.14%
ROE(3y)-7.71%
ROE(5y)0.4%
ROIC(3y)N/A
ROIC(5y)N/A
GRX Yearly ROA, ROE, ROICGRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRX Yearly Profit, Operating, Gross MarginsGRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, GRX has about the same amount of shares outstanding.
GRX has less shares outstanding than it did 5 years ago.
GRX has a worse debt/assets ratio than last year.
GRX Yearly Shares OutstandingGRX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
GRX Yearly Total Debt VS Total AssetsGRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

GRX has an Altman-Z score of 2.93. This is not the best score and indicates that GRX is in the grey zone with still only limited risk for bankruptcy at the moment.
The Debt to FCF ratio of GRX is 1.00, which is an excellent value as it means it would take GRX, only 1.00 years of fcf income to pay off all of its debts.
GRX has a Debt/Equity ratio of 0.20. This is a healthy value indicating a solid balance between debt and equity.
Even though the debt/equity ratio score it not favorable for GRX, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF 1
Altman-Z 2.93
ROIC/WACCN/A
WACCN/A
GRX Yearly LT Debt VS Equity VS FCFGRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

GRX has a Current Ratio of 4.51. This indicates that GRX is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 4.51 indicates that GRX has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 4.51
Quick Ratio 4.51
GRX Yearly Current Assets VS Current LiabilitesGRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

0

3. Growth

3.1 Past

GRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 86.11%, which is quite impressive.
The Revenue has decreased by -0.82% in the past year.
GRX shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.67% yearly.
EPS 1Y (TTM)86.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.86%
Revenue 1Y (TTM)-0.82%
Revenue growth 3Y2.57%
Revenue growth 5Y-0.67%
Sales Q2Q%-2.96%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GRX Yearly Revenue VS EstimatesGRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRX Price Earnings VS Forward Price EarningsGRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF 4.33
EV/EBITDA N/A
GRX Per share dataGRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

4

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 6.93%, GRX is a good candidate for dividend investing.
GRX's Dividend Yield is rather good when compared to the S&P500 average which is at 2.44.
Industry RankSector Rank
Dividend Yield 6.93%

5.2 History

GRX has paid a dividend for at least 10 years, which is a reliable track record.
GRX has decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years2
GRX Yearly Dividends per shareGRX Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8

5.3 Sustainability

The earnings of GRX are negative and hence is the payout ratio. GRX will probably not be able to sustain this dividend level.
DP-1357.75%
EPS Next 2YN/A
EPS Next 3YN/A
GRX Yearly Income VS Free CF VS DividendGRX Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

More info and screens

GABELLI HEALTHCARE & WELL

NYSE:GRX (10/8/2025, 8:04:00 PM)

9.27

+0.04 (+0.43%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners37.35%
Inst Owner Change0%
Ins Owners1.83%
Ins Owner Change0%
Market Cap143.22M
Analysts0
Price TargetN/A
Short Float %0.01%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield 6.93%
Yearly Dividend0.59
Dividend Growth(5Y)N/A
DP-1357.75%
Div Incr Years0
Div Non Decr Years2
Ex-Date09-16 2025-09-16 (0.17)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 38.09
P/FCF 4.33
P/OCF 4.33
P/B 0.88
P/tB 0.88
EV/EBITDA N/A
EPS(TTM)-0.05
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)2.14
FCFY23.09%
OCF(TTM)2.14
OCFY23.09%
SpS0.24
BVpS10.55
TBVpS10.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.36%
ROE -0.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 879.52%
ROA(3y)-6.34%
ROA(5y)0.14%
ROE(3y)-7.71%
ROE(5y)0.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF 1
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.51
Quick Ratio 4.51
Altman-Z 2.93
F-Score8
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)86.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.86%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-0.82%
Revenue growth 3Y2.57%
Revenue growth 5Y-0.67%
Sales Q2Q%-2.96%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-10.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.01%
OCF growth 3YN/A
OCF growth 5YN/A